CD5 CAR T cells control progression of T-ALL in xenograft mouse models. (A) Jurkat-FFluc cells (3 × 106 per mouse) were IV injected followed by IV injection of CAR T cells (10 × 106 per mouse) on days 3 and 6 postimplantation. Tumor burden was assessed by IVIS imaging at indicated time points. (B) Kaplan–Meier survival curve; mice were euthanized after developing hind limb paralysis. (C) Eradication of systemic disease by CD5 CAR T cells. Mice were engrafted with Jurkat-FFluc cells, which established systemic disease by day 6. (D) Total luminescence from Jurkat cells recorded on day 6 (prior to CAR T-cell injection) and day 12. (E) Kaplan–Meier survival curve for eradication of systemic disease. (F) CCRF-CEM–FFluc cells (1 × 106 per mouse) were IV injected followed by IV injection of CAR T cells (10 × 106 per mouse) on day 3 and 6 post-implantation. Tumor burden was assessed by IVIS imaging at indicated time points. (G) Relative frequency CCRF-GFP in peripheral blood of mice on day 18 post-engraftment is shown on representative dot plots. (H) Kaplan–Meier survival curve for the CCRF model. P values are shown for each experiment.
